Product Information
HYZAAR 100-25 TABLET is a brand product labeled by Organon LLC, priced at $6.7968 per EA under NDC 78206014102. Its NADAC has been published 241 times since Feb 23, 2022.
FDA first approved this application on Apr 28, 1995. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the losartan potassium and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25; 100 mg/1; mg/1
Manufacturer
Organon LLCNDC
78206014102
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUMApproval Type
New Drug (NDA)
FDA Application
NDA020387FDA Approved
4/28/1995
TE Code
AB
On Market Since
6/1/2021
Pharmacological Classes
Price Statistics
The NADAC for HYZAAR 100-25 TABLET has been published 241 times since Feb 23, 2022, and over the history we have for it it has risen 21.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.7968 per EA |
|---|---|
| All-time high | $6.8321 (Sep 16, 2026) |
| All-time low | $5.5924 (Feb 23, 2022) |
| 52-week high | $6.8321 |
| 52-week low | $6.4948 |
| Median price | $6.1826 |
| Average price | $6.2061 |
| Largest weekly change | +6.0% (Jan 18, 2023) |
| Weeks tracked | 241 |
| Tracking since | Feb 23, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Organon LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
losartan potassium and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYZAAR 100-25 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HYZAAR 100-25 TABLET, manufactured by Organon LLC, is $6.7968 per EA (NDC 78206014102), effective Sep 30, 2026.
How has the price of HYZAAR 100-25 TABLET changed over time?
Over the history we have for it, the NADAC for HYZAAR 100-25 TABLET has risen 21.5%. It has been tracked across 241 weekly CMS publications since Feb 23, 2022.
What are the highest and lowest recorded NADAC prices for HYZAAR 100-25 TABLET?
Since Feb 23, 2022, the NADAC for HYZAAR 100-25 TABLET has ranged from a low of $5.5924 (Feb 23, 2022) to a high of $6.8321 (Sep 16, 2026), with a median of $6.1826 per EA.
Are there cheaper alternatives to HYZAAR 100-25 TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LOSARTAN-HYDROCHLOROTHIAZIDE 100-25 MG TAB, is $0.0793 per EA — about 99% below HYZAAR 100-25 TABLET.
Who manufactures HYZAAR 100-25 TABLET?
HYZAAR 100-25 TABLET (NDC 78206014102) is labeled by Organon LLC, and CMS classifies it as a brand product.